Home / TELO : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does TELO make money? Does TELO have pricing power? What's the Earnings Whisper? Will TELO profit more as the business scales? What is TELO's management track record? Is TELO's current price justified?

Telomir Pharmaceuticals, Inc. Common Stock

$1.17 -$0.17 (-12.69%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$1.17

Day Range

$1.11$1.2

Year Range

$0.89$2.09

Market Cap

80.47M

AVG Volume

91.33K

Trailing/Forward PE

-0.77/-

PEG ratio

0.08

Dividend Yield

Next Earnings Date

2026-12-02

Primary Exchange

NASDAQ

Net Income (USD) · TTM

TELO Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-5.88M
26 Q1	-9.22M
25 Q4	-10.41M
25 Q3	-11.25M
25 Q2	-16.14M
25 Q1	-12.52M
24 Q4	-16.59M
24 Q3	-23.02M
24 Q2	-18.74M
24 Q1	-18.84M

Operating Income (USD) · TTM

TELO Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-6.09M
26 Q1	-9.39M
25 Q4	-10.54M
25 Q3	-11.31M
25 Q2	-16.17M
25 Q1	-12.57M
24 Q4	-12.3M
24 Q3	-10.48M
24 Q2	-5.42M
24 Q1	-5.38M

EBITDA (USD) · TTM

TELO EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-5.87M
26 Q1	-9.22M
25 Q4	-10.41M
25 Q3	-11.25M
25 Q2	-16.14M
25 Q1	-12.49M
24 Q4	-10.31M
24 Q3	-15.98M
24 Q2	-10.94M
24 Q1	-10.95M

Cash Flows (USD) · TTM

TELO Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-4.91M
26 Q1	-4.6M
25 Q4	-3.69M
25 Q3	-3.09M
25 Q2	-3.17M
25 Q1	-3.99M
24 Q4	-5.07M
24 Q3	-5.55M
24 Q2	-6.55M
24 Q1	-5.06M

EPS (USD) · TTM

TELO EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-1.51
26 Q1	-0.29
25 Q4	-0.34
25 Q3	-0.38
25 Q2	-0.54
25 Q1	-0.42
24 Q4	-0.58
24 Q3	-0.8
24 Q2	-0.66
24 Q1	-0.66

Expenses (USD) · TTM

TELO Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	6.09M
26 Q1	9.39M
25 Q4	10.54M
25 Q3	11.31M
25 Q2	16.17M
25 Q1	12.57M
24 Q4	11.93M
24 Q3	9.63M
24 Q2	4.57M
24 Q1	3.83M

Shares Outstanding · TTM

TELO Shares Outstanding · TTM by quarter
Period	Shares Outstanding · TTM
26 Q2	503.32K
26 Q1	-3.92M
25 Q4	-5.3M
25 Q3	-7.36M
25 Q2	-12.91M
25 Q1	-8.24M
24 Q4	-6.87M
24 Q3	-4.81M
24 Q2	0
24 Q1	0

Employee Count

TELO Employee Count by quarter
Period	Employee Count
2025	2
2024	5
2023	1

Free Cash Flow Yield

TELO Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-12.22%
Sep 26	-12.22%
Sep 26	-12.32%
Aug 26	-12.54%
Aug 26	-12.65%
Aug 26	-13.11%
Aug 26	-11.53%
Jul 26	-11.05%
Jul 26	-11.63%
Jul 26	-12.05%
Jul 26	-10.87%
Jul 26	-10.53%
Jun 26	-10.79%
Jun 26	-9.42%
Jun 26	-10.62%
Jun 26	-11.05%
May 26	-10.29%
May 26	-10.37%
May 26	-10.62%
May 26	-8.25%
May 26	-7.66%
Apr 26	-7.66%
Apr 26	-7.4%
Apr 26	-8.79%
Apr 26	-8.45%
Mar 26	-8.58%
Mar 26	-8.13%
Mar 26	-7.55%
Mar 26	-7.97%
Feb 26	-7.85%
Feb 26	-8.74%
Feb 26	-9.14%
Feb 26	-8.66%
Jan 26	-8.74%
Jan 26	-7.44%
Jan 26	-7.17%
Jan 26	-7.33%
Jan 26	-7.44%
Dec 25	-6.82%
Dec 25	-7.07%
Dec 25	-6.87%
Dec 25	-7.27%
Nov 25	-7.44%
Nov 25	-7.78%
Nov 25	-7.38%
Nov 25	-8.06%
Oct 25	-6.77%
Oct 25	-7.04%
Oct 25	-6.72%
Oct 25	-6.4%
Oct 25	-7.54%
Sep 25	-7.59%
Sep 25	-6.9%
Sep 25	-7.76%
Sep 25	-8.51%
Aug 25	-8%
Aug 25	-7.28%
Aug 25	-7.08%
Aug 25	-8.6%
Aug 25	-7.62%
Jul 25	-6.13%
Jul 25	-5.89%
Jul 25	-11.57%
Jul 25	-11.67%
Jun 25	-8.77%
Jun 25	-7.62%
Jun 25	-6.85%
Jun 25	-6.24%
May 25	-6.88%
May 25	-6.39%
May 25	-5.37%
May 25	-6.89%
May 25	-6.63%
Apr 25	-6.73%
Apr 25	-6.92%
Apr 25	-6.38%
Apr 25	-5.86%
Mar 25	-4.35%
Mar 25	-3.76%
Mar 25	-3.75%
Mar 25	-3.95%
Feb 25	-4.29%
Feb 25	-4.39%
Feb 25	-4%
Feb 25	-3.93%
Jan 25	-3.86%
Jan 25	-3.73%
Jan 25	-4%
Jan 25	-4.56%
Jan 25	-4.15%
Dec 24	-3.85%
Dec 24	-3.62%
Dec 24	-3.61%
Dec 24	-2.88%
Nov 24	-4.71%
Nov 24	-4.42%
Nov 24	-5.03%
Nov 24	-5.24%
Nov 24	-5.21%
Oct 24	-4.98%

Price to Book

TELO Price to Book by quarter
Period	Price to Book
Sep 26	7.99
Sep 26	7.99
Sep 26	7.92
Aug 26	7.79
Aug 26	7.72
Aug 26	7.45
Aug 26	8.04
Jul 26	8.38
Jul 26	7.97
Jul 26	7.69
Jul 26	8.52
Jul 26	8.8
Jun 26	8.59
Jun 26	9.84
Jun 26	8.73
Jun 26	8.38
May 26	9.01
May 26	8.94
May 26	8.73
May 26	7.56
May 26	8.14
Apr 26	8.14
Apr 26	8.43
Apr 26	7.09
Apr 26	7.38
Mar 26	7.27
Mar 26	7.67
Mar 26	5.87
Mar 26	5.56
Feb 26	5.65
Feb 26	5.07
Feb 26	4.85
Feb 26	5.11
Jan 26	5.07
Jan 26	5.96
Jan 26	6.18
Jan 26	6.05
Jan 26	5.96
Dec 25	6.49
Dec 25	6.27
Dec 25	6.45
Dec 25	6.09
Nov 25	5.96
Nov 25	5.69
Nov 25	6
Nov 25	81.69
Oct 25	97.29
Oct 25	93.54
Oct 25	97.91
Oct 25	102.9
Oct 25	87.31
Sep 25	86.68
Sep 25	95.41
Sep 25	84.81
Sep 25	77.33
Aug 25	82.32
Aug 25	90.43
Aug 25	92.92
May 25	114.38
May 25	118.98
Apr 25	117.14
Apr 25	113.92
Apr 25	123.57
Apr 25	134.6
Mar 25	181.45
Mar 25	209.47
Mar 25	210.39
Mar 25	199.83
Feb 25	183.75
Feb 25	179.61
Feb 25	197.07
Feb 25	200.74
Jan 25	325.52
Jan 25	336.91
Jan 25	314.13
Jan 25	275.28
Jan 25	302.75
Dec 24	326.19
Dec 24	346.95
Dec 24	348.29
Dec 24	436.71
Nov 24	266.58
Nov 24	283.99
Nov 24	249.83
Nov 24	79.71
Nov 24	80.28
Oct 24	83.87
Oct 24	88.78
Oct 24	95.77
Oct 24	102.57
Sep 24	128.82
Sep 24	148.09
Sep 24	114.66
Sep 24	97.28
Aug 24	98.98
Aug 24	99.17
Aug 24	75.37
Aug 24	41.64
Aug 24	32.42
Jul 24	37.66

No video analysis for this stock yet. Request one from our team.

News: TELO

globenewswire.com · 14 Sep 2026

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models.

defenseworld.net · 12 Aug 2026

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) were down 3.4% during mid-day trading on Tuesday. The company traded as low as $1.13 and last traded at $1.13. 27,578 shares traded hands during trading, a decline of 74% from the average daily volume of 104,128 shares. The stock had previously closed at

accessnewswire.com · 15 Jun 2026

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes mellitus (T2DM).